EUROPEAN COMMISSION AUTHORISES ViiV HEALTHCARE’S APRETUDE (CABOTEGRAVIR LONG-ACTING AND TABLETS) FOR HIV PREVENTION
Given as few as six times per year, cabotegravir has demonstrated superior efficacy to a daily oral PrEP option (FTC/TDF tablets) in reducing the risk of HIV acquisition in clinical trials.1,2,3,4 With approximately 100,000 people newly diagnosed with HIV each year in Europe,5 expanding HIV prevention options is crucial in reducing HIV transmission. London, 19 September […]